Intensified omeprazole treatment to reduce high-output stoma in ileostomy patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of intensified omeprazole therapy in reducing high-output stoma (HOS) in adults undergoing ileostomy surgery. The study compares the mean daily ileostomy output between patients receiving intensified omeprazole treatment and those on standard therapy during the first three postoperative days. It also assesses the incidence of dehydration-related complications and the overall length of hospital stay. By investigating the potential benefits of omeprazole in managing excessive stoma output, the trial aims to improve patient outcomes following ileostomy procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 years or older
* Scheduled for elective or emergency surgery requiring end or loop ileostomy formation
* Able and willing to provide written informed consent
* No contraindications to omeprazole use

Exclusion Criteria:

* Pregnancy or lactation
* Known hypersensitivity or allergy to proton pump inhibitors (including omeprazole)
* Conditions preventing accurate measurement of daily ileostomy output

Where it's running

• Department of Oncological, Transplant and General Surgery, Univeristy Clinical Center
  Gdansk, Pomeranian Voivodeship, Poland Recruiting
• Clinical Department of Oncologic Surgery with a Subdivision of Breast, Skin, and Soft Tissue Tumor Surgery PCK Maritime Hospital
  Gdynia, Poland Recruiting

Study contacts

• Study coordinator: Tomasz Sylwestrzak, MD
• Email: tomasz.sylwestrzak@gumed.edu.pl
• Phone: +48516077708

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Maternal and infant microbiome links to infant gut inflammation and pregnancy outcomes in people with IBD

  This project will see if mothers' microbiomes, diets, and breastmilk are linked to infant gut inflammation (measured by fecal calprotectin) in pregnant people with and without IBD.

  Recruiting University of British Columbia · Vancouver, British Columbia and 1 other locations · NCT07385807

• Infliximab plus the Crohn's Disease Exclusion Diet for children with Crohn's disease

  This will test whether starting a Crohn's Disease Exclusion Diet at the same time as infliximab helps children with moderate-to-severe Crohn's disease get better and stay in remission.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT07314606

• SMART-IBD app for teens with inflammatory bowel disease

  This will test whether the SMART-IBD smartphone app helps adolescents ages 13–17 with IBD take their medicines and manage symptoms better than completing daily diaries alone.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07195123

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

• ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

  This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07841236

• Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer

  This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07840677

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.